Hot Features
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unr... Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.231 | -15.1973684211 | 1.52 | 1.5499 | 1.22 | 157127 | 1.3317848 | CS |
| 4 | -0.681 | -34.5685279188 | 1.97 | 2.12 | 1.22 | 127207 | 1.66287318 | CS |
| 12 | -0.971 | -42.9646017699 | 2.26 | 2.46 | 1.22 | 213157 | 1.85707269 | CS |
| 26 | -1.861 | -59.0793650794 | 3.15 | 3.23 | 1.22 | 152093 | 2.11764027 | CS |
| 52 | -10.011 | -88.592920354 | 11.3 | 12.23 | 1.22 | 135164 | 4.36165767 | CS |
| 156 | -0.111 | -7.92857142857 | 1.4 | 12.23 | 0.17 | 1746689 | 4.12417968 | CS |
| 260 | -12.521 | -90.6661839247 | 13.81 | 41 | 0.17 | 1124640 | 4.55733933 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.